Should You Retain Henry Schein Stock in Your Portfolio for Now?

Core Insights - Henry Schein, Inc.'s joint venture, Henry Schein One, is experiencing strong growth in core products and new solutions, supported by a robust partnership strategy [1][3] - The company has faced headwinds from a sluggish macroeconomic environment and intense competition, which may impact operations [1][10] Financial Performance - Over the past year, Henry Schein's stock has increased by 6.4%, while the industry grew by 7.7% and the S&P 500 composite rose by 17.6% [2] - The company has a market capitalization of $8.29 billion and has beaten earnings estimates in three of the last four quarters, with an average surprise of 2.1% [2] Growth Drivers - Henry Schein One is benefiting from the adoption of cloud-based practice management software, with over 11,000 customers subscribed to its solutions [3] - A new partnership with Amazon Web Services will integrate generative AI technologies into the Henry Schein One ecosystem, enhancing AI-powered dentistry [4] - The introduction of LinkIt provides a seamless digital workflow for dental teams, connecting various digital imaging and planning systems [5] Expansion Strategies - The company has expanded its revenue growth through niche acquisitions and partnerships, including becoming the exclusive U.S. distributor for vVARDIS's Curodont Repair Fluoride Plus product [6] - A strategic partnership with Oral Genome aims to distribute innovative saliva testing solutions nationwide [7] - The acquisition of Acentus enhances Henry Schein's homecare medical products platform, while the acquisition of R. Weinstein, Inc. expands its presence in Hawaii [8] Challenges - The macroeconomic environment, including exchange rate fluctuations, inflation, and recession, is negatively impacting Henry Schein's financial operations [10] - The company's gross margin contracted by 19 basis points due to an 8% rise in the cost of sales, and SG&A expenses increased by 9.5% to $808 million [11] - The competitive landscape in the healthcare products distribution industry is intense, affecting market share and operational results [12] Future Outlook - The Zacks Consensus Estimate for Henry Schein's 2026 earnings per share has increased by 3 cents to $5.30, with revenues projected to rise by 3.9% to $13.70 billion [13]